Publications by authors named "K Shaver"
In vivo T-cell depletion (TCD) using alemtuzumab decreases the risk of Graft vs Host Disease (GvHD) in recipients of allogeneic hematopoietic stem cell transplant (allo-HSCT). However, this approach increases the risk of infections post-allo-HSCT, including Cytomegalovirus (CMV). Letermovir is approved for the use in CMV prophylaxis post-allo-HSCT.
View Article and Find Full Text PDFBlinatumomab, a bispecific T cell engager that binds CD19 in leukemic cells and CD3 in cytotoxic T cells and leads to leukemic blast lysis, is often used in pediatric patients with relapsed/refractory (R/R) B cell acute lymphoblastic leukemia (B-ALL) prior to allogeneic hematopoietic cell transplantation (allo-HCT). Concerns about the potential risk of blinatumomab-related immune-mediated toxicities after allo-HCT have not been adequately addressed. These include graft-versus-host disease (GVHD), delayed engraftment, and graft failure or rejection.
View Article and Find Full Text PDFBackground: Finding the ideal candidate for a residency/fellowship program has always been difficult. Finding the "perfect" match has always been the ultimate goal. However, many factors affect obtaining that "perfect" match.
View Article and Find Full Text PDFArticle Synopsis
- Cancer immunotherapy enhances the body's immune system to fight tumors, but current approaches, like PD-1/PD-L1 blockade, often have low overall response rates, particularly in advanced cancers.
- Natural Killer (NK) cells are crucial for both the innate and adaptive immune responses, and their early activation can significantly improve the effectiveness of immunotherapies, despite many patients having compromised NK cell function.
- Adoptive allogeneic NK cell therapies show promise in boosting immunotherapy responses and are being explored in combination with other immune-oncology strategies to enhance treatment outcomes.
Objective: To compare the visual outcomes between macula-on and macula-off primary rhegmatogenous retinal detachment (RRD) based on the duration of macular detachment (DMD).
Methods And Analysis: Retrospective study including 96 eyes with RRD (34 macula-on and 62 macula-off) repaired between June 2012 and March 2020. The final visual acuity (VA) was compared after the patients were divided by the status of the macula and their DMD.